Overview

Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy

Status:
Approved for marketing

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The expanded access program will provide access to treatment with deflazacort in children, adolescent, and adult patients with DMD in the U.S. who are ineligible, unable, or otherwise unwilling to enroll in a clinical study examining the efficacy of deflazacort while a new drug application is under preparation and review. Enrollment is open to all eligible patients.

Details

Lead Sponsor:

Marathon Pharmaceuticals, LLC
PTC Therapeutics

Collaborators:

Dohmen Life Science Services
Parexel

Treatments:

Deflazacort